MAP – Microba Life Sciences Limited

I became interested … but don’t know enough about the company to invest, especially with the price dropping so …

40c three years ago

$5 million raised to fund path to cashflow break-even and continued core testing growth​

Key Highlights
• $5.0 million placement secured at $0.05 per share, supported by existing and new institutional and sophisticated investors
• Major strategic partner and shareholder, Sonic Healthcare Limited (ASX: SHL), is investing $1.5 million as part of the Placement
• The Placement combined with streamlined and AI enhanced operations delivers the path to whole company cashflow break-even
• Core testing growth momentum continues – 11 consecutive quarters of core testing sales growth and 106% growth in last 12 months core testing sales, increasingly driven by enterprise-style healthcare clinic contracts
• A new category-defining testing product is on track to launch in Q3 CY26, a catalyst for the next phase of Diagnostics growth
• Eligible shareholders can apply for up to $30,000 of new shares under the $1.0 million Share Purchase Plan at the same $0.05 offer price
• For every one (1) New Share subscribed for by all participants under the Placement and SPP, Microba will issue one (1) attaching unlisted option, exercisable at $0.0625 and expiring three years from the date of issue, subject to shareholder approval.

Microba Life Sciences is a company at the forefront of microbiome diagnostics & therapeutics and are on a mission to improve human health. With world-leading technology for measuring the human gut microbiome, Microba operates two business divisions: a clinical microbiome diagnostics division delivering gut microbiome testing services globally to clinicians and patients, and a clinical-stage therapeutics division focused on the discovery, development and commercialisation of novel microbiome-derived live biotherapeutic products.